Idera Pharmaceuticals Announces Results of Phase 1 Clinical Trial of IMO-8400, Toll-like Receptor Antagonist Drug Candidate for Autoimmune and Inflammatory Diseases
IMO-8400 Demonstrates Favorable Safety Profile
Sustained Inhibition of Targeted TLR 7-, 8-, and 9-mediated Cytokine Induction Observed
Phase 2 Trial of IMO-8400 in Patients with Moderate-to-Severe Plaque Psoriasis Ongoing
"We are very pleased with the safety and tolerability of IMO-8400 in
this trial. Further, IMO-8400 showed strong and sustained inhibition of
TLR7-, 8-, and 9- mediated cytokine induction," said
“We anticipate data from the ongoing Phase 2 trial to be available by
year-end. Results from this study will inform our decisions regarding
later stage clinical development of IMO-8400 in patients with psoriasis
and clinical development in other indications,” said
Phase 1 Clinical Trial Results
- IMO-8400 was well tolerated in single- and multiple-dose regimens at all dosages
- The intended pharmacodynamic mechanism of action was demonstrated in IMO-8400 treated subjects
- Cytokine induction mediated by TLRs 7, 8, and 9 was inhibited in IMO-8400 treated subjects and not in placebo treated subjects
- The induction of multiple cytokines was inhibited, including TNF-α, IL-1β, IL-6 and IFN-α
- Inhibition of cytokine induction was sustained for seven days after dosing with IMO-8400
- Pharmacokinetics showed IMO-8400 was rapidly cleared from plasma with no accumulation
- Pharmacodynamic results support a weekly dose regimen for evaluation of IMO-8400 in clinical development in autoimmune disease indications
About the IMO-8400 Phase 1 Trial in Healthy Subjects
A Phase 1 clinical trial of IMO-8400 was conducted to assess the safety, pharmacokinetic and pharmacodynamic activity in healthy subjects. This randomized, double-blind, placebo controlled trial enrolled 42 healthy subjects. The single-dose portion of the trial involved three escalating dose levels of 0.1, 0.3 and 0.6 mg/kg of IMO-8400 or placebo, with six subjects receiving each treatment. The multiple-dose portion of this trial involved two dose levels of IMO-8400, 0.3 and 0.6 mg/kg, and placebo, with six subjects receiving each treatment for four weekly doses. Safety and tolerability were monitored throughout the study. Pharmacokinetic activity and pharmacodynamic activity were monitored at specific times.
About the Ongoing IMO-8400 Phase 2 Trial in Patients with Moderate to Severe Plaque Psoriasis
The Phase 2 trial is a randomized, double-blind, placebo-controlled trial of IMO-8400 monotherapy in patients with moderate to severe plaque psoriasis. In this trial, 32 patients with PASI scores of 12.0 or greater will be randomized 1:1:1:1 to receive weekly subcutaneous doses of IMO-8400 at 0.075, 0.15, or 0.3 mg/kg/week or placebo for 12 weeks. Safety and improvements in PASI score will be monitored throughout the trial.
About TLRs and Idera's Pipeline
Toll-like Receptors (TLRs) play a key role in immunity and inflammation. Using a chemistry-based approach, Idera has created compounds targeted to endosomal TLRs 3, 7, 8, and 9. In autoimmune diseases, immune complexes containing host DNA/RNA activate TLRs 7, 8, and 9, which induce multiple cytokines that further exacerbate the disease. Inhibition of these TLRs is a novel approach for the potential treatment of autoimmune diseases. IMO-8400 is an antagonist of TLRs 7, 8, and 9, and has shown therapeutic activity in preclinical models of psoriasis, lupus, and arthritis. Our proof-of-concept Phase 2 trial of TLR antagonism in patients with psoriasis using a TLR7 and 9 antagonist, IMO-3100, showed PASI score improvements which correlated with significant improvement in psoriasis disease associated gene profile, including downregulation of the IL-17 pathway.
About
Idera Forward Looking Statements
This press release contains forward-looking statements concerning
Source:
Idera Pharmaceuticals, Inc.
Lou Arcudi, 617-679-5517
larcudi@iderapharma.com